Search
for
Sort by
Research 121–150 of 532
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Ritlecitinib in severe alopecia areata: a profile of its use
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Ritlecitinib: First Approval
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- 1323 The effects of 3-OH of kaempferol on interfollicular epidermal stem cell fate
- 1324 Impairment of hair-inducing capacity of 3D-cultured human dermal papilla cells by the ablation of STAT5
- 1327 Effect of ginsenoside Rd on dermal epidermal junction in fibroblast
- 1325 Age-dependent loss of the stemness and antimicrobial defense function of dermal fibroblasts is mediated by TGFbeta
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- Alopecia areata
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
- Tofacitinib for the treatment of lichen planopilaris: A case series